A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
Latest Information Update: 28 Jul 2025
At a glance
- Drugs ALC 2203 (Primary)
- Indications Bronchiolitis
- Focus Therapeutic Use
- Sponsors Korea arlico Pharm
Most Recent Events
- 28 Jul 2025 New trial record